EFFICACY OF CARDIOVERTER-DEFIBRILLATORS IN PREVENTION OF SUDDEN DEATH AND OVERALL MORTALITY DECREASE IN PATIENTS WITH THE SYNDROME OF DILATION CARDIOMYOPATHY: DIFFERENTIAL APPROACH

Aim. To evaluate the exact efficacy of the implantable cardioverter-defibrillators (ICD) and combination devices (CRT-D), and to evaluate their influence on the rate of sudden death and overall mortality in patients with the dilation cardiomyopathy syndrome (DCMP), and to clarify the selection criteria for implantation.

Material and methods. Totally, 220 DCMP patients investigated: 66 (30%) of them (mean age 48,5±12,8 y. o., 47 males) underwent implantation of ICD (n=37) and CRT-D (n=29), 154 (70%) patients were in comparison group (mean age 47,1±12,4 y. o., 104 males). In 60 patients (93,9%) the devices were implanted for primary prevention of sudden cardiac death (SCD). Follow-up lasted for 16 [6; 37] months. As primary endpoints, the following parameters were used: “death+transplantation”, mortality, SCD, “SCD+shock” and “death+transplantation+proper shocks of the defibrillators”.

Results. Mortality in all DCMP patients was 19,1%, “death+transplantation” — 21,4%, SCD — 2,7%. There were no significant differences by these values in patients with both devices (19,7%; 22,7% and 1,5%), ICD (21,6%; 24,3% and 2,7%), CRT-D (17,2%; 20,7; and 0) and patients with no devices (18,8%; 20,8% and 3,2%). Significantly higher rates by “SCD+shocks” (18,2% v 3,2%, p<0,001) and “death+transplantation+shocks” (36,4% vs 20,8%, p<0,05) in patients with the implanted devices witness for real impact of the defibrillators in equality of overall mortality and SCD parameters. Among the patients with implanted devices, the genetic and mixed (genetic and inflammatory) nature of DCMP predominated (62,1 v 35,7%, p<0,001), there was significantly lower EF (26,3±9,2 v 30,7±10,3%, p<0,01), its end value (31,1±11,0 v 39,2±13,5%, p<0,01), significantly higher end diastolic size of the left ventricle (EDS, LV, 6,8±0,8 v 6,5±0,8 cm, p<0,05) and the grade of mitral regurgitation. In patients with the devices, rate of proper shocks was 18,2%. In isolated myocarditis there were no shocks (35,3±9,1% v 26,8±9,3%, p<0,05), EDS significantly lower (6,2±0,6 cm v 6,9±0,9 cm, p<0,01), ECG signs of LV hypertrophy were more rare (16,7% v 56,3%, p<0,05), but more commonly — the low voltage of QRS (33,3% v 10,6%, p=0,53); there were no differences in the rates of cardiotropic drugs prescription. Main predictors of the shocks were genetic origin of DCMP (isolated or with myocarditis, 25/75%, comparing with 20/33% in patients with no shocks, p<0,01, HR 1,58, OR 10,93, sensitivity 94,1%, negative predictive value 99,2%), and sustained (HR 18,0, sensitivity 98,1%) and non-sustained ventricular tachycardia (HR 1,43, sensitivity and negative predictive value 100%), decrease of QRS voltage and absence of the signs of LV hypertrophy on ECG (negative predictive value 92,8% and 95,6%).

Conclusion. In DCMP patients, implanting of ICD/CRT-D was performed with acknowledged additional criteria (genetic or mixed DCMP etiology, lower EF and worse response to treatment); due to more effective ICD therapy, the values of mortality, “death+transplantation” and SCD were not higher than in less severe patients with no such devices. Proper shocks developed in patients with significantly higher EF. As an independent SCD risk factor and a criteria for patients selection to defibrillator implantation, genetic origin of DCMP should be used, especially if comorbid with myocarditis. As the predictors for benign outcome — absence of non-sustained ventricular tachycardia, lower QRS voltage, signs of LV hypertrophy on ECG. An algorithm proposed of DCMP patients selection for ICD treatment.

dilation cardiomyopathy, myocarditis, sudden death, cardioverterdefibrillator, ventricular tachicardia

1. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994; 331: 1564-75.

2. Castelli G, Fornaro A, Ciaccheri M, et al. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. Circ Heart Fail. 2013; 6 (5): 913-21. DOI: 10.1161/CIRCHEARTFAILURE.112.000120.

3. Morentin B, Audicana C. Population-based study of out-of-hospital sudden cardiovascular death: incidence and causes of death in middle-aged adults. Rev Esp Cardiol. 2011; 64 (1): 28-34. DOI: 10.1016/j.recesp.2010.07.002.

4. Merlo M, Pivetta A, Pinamonti B, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 2014; 16 (3): 317-24. DOI: 10.1002/ejhf.16.

5. Elliott P, Charron P, Blanes JR, et al. EORP Cardiomyopathy Registry Pilot Investigators. Eur Heart J. 2016; 37 (2): 164-73. DOI: 10.1093/eurheartj/ehv497.

6. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015; 36 (41): 2793-867. DOI: 10.1093/eurheartj/ehv316.

7. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352 (3): 225-37.

8. Køber L, Thune JJ, Nielsen JC, et al. DANISH Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016; 375 (13): 1221-30. DOI: 10.1056/NEJMoa1608029.

9. Wolff G, Lin Y, Karathanos A, et al. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clin Res Cardiol. 2017; 106 (7): 501-13. DOI: 10.1007/s00392-017-1079-0.

10. Cavalcanti R, Aboul-Hosn N, Morales G, Abdel-Latif A. Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy. Angiology. 2017:3319717710851. DOI: 10.1177/0003319717710851.

11. Stavrakis S, Asad Z, Reynolds D. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Electrophysiol. 2017; 28 (6): 659-65. DOI: 10.1111/jce.13204.

12. Akel T, Lafferty J. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis. Cardiovasc Ther. 2017; 35 (3). DOI: 10.1111/1755-5922.12253.

13. Goldberger JJ, Subačius H, Patel T, et al. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2014; 63 (18): 187989. DOI: 10.1016/j.jacc.2013.12.021.

14. Demming T, Sandrock S, Kuhn C, et al. Deceleration capacity: A novel predictor for total mortality in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol. 2016; 221: 289-93. DOI: 10.1016/j.ijcard.2016.06.205.

15. Sedov AV, Tsaregorodtsev DA, Sulimov VA. Non-invasive electrophysiological markers of higher risk for fatal outcomes in dilation cardiomyopathy patients. Russian Journal of Cardiology. 2017; 2 (142): 50-61. (In Russ.) Седов А. В., Царегородцев Д. А., Сулимов В. А. Неинвазивные электрофизиологические маркеры высокого риска фатальных событий у больных с дилатационной кардиомиопатией. Российский кардиологический журнал. 2017; 2 (142): 50-61. DOI: 10.15829/1560-4071-2017-2-50-61.

16. Blagova OV, Nedostup AV, Kogan EA, et al. Dilated cardiomyopathy as clinical syndrome: experience with nosological diagnostics with biopsy and treatment approaches. Ter Arkh. 2011; 83 (9): 41-8. (In Russ.). Благова О. В., Недоступ А. В., Коган Е. А., и др. Дилатационная кардиомиопатия как клинический синдром: опыт нозологической диагностики с использованием биопсии и подходы к лечению. Терапевтический архив. 2011; 83 (9): 41-8.

17. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016; 37 (23): 1850-8. DOI: 10.1093/eurheartj/ehv727.

18. Schliamser JE, Kadish AH, Subacius H, et al. DEFINITE Investigators. Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in NonIschemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). Heart Rhythm. 2013; 10 (6): 838-46. DOI: 10.1016/j.hrthm.2013.02.017.

19. Grimm W, Timmesfeld N, Efimova E. Left ventricular function improvement after prophylactic implantable cardioverter-defibrillator implantation in patients with nonischaemic dilated cardiomyopathy. Europace. 2013; 15 (11): 1594-600. DOI: 10.1093/europace/eut097.

20. Perazzolo Marra M, De Lazzari M, Zorzi A, et al. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Heart Rhythm. 2014; 11 (5): 85663. DOI: 10.1016/j.hrthm.2014.01.014.

21. Piers SR, Everaerts K, van der Geest RJ, et al. Myocardial scar predicts monomorphic ventricular tachycardia but not polymorphic ventricular tachycardia or ventricular fibrillation in nonischemic dilated cardiomyopathy. Heart Rhythm. 2015 Oct; 12 (10): 2106-14. DOI: 10.1016/j.hrthm.2015.05.026.

22. Gaztanaga J, Paruchuri V, Elias E, et al. Prognostic Value of Late Gadolinium Enhancement in Nonischemic Cardiomyopathy. Am J Cardiol. 2016; 118 (7): 1063-8. DOI: 10.1016/j.amjcard.2016.06.059.

23. Memon S, Ganga HV, Kluger J. Late Gadolinium Enhancement in Patients with Nonischemic Dilated Cardiomyopathy. Pacing Clin Electrophysiol. 2016; 39 (7): 731-47. DOI: 10.1111/pace.12873.

24. Halliday BP, Gulati A, Ali A, et al. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation. 2017; 135 (22): 2106-15. DOI: 10.1161/CIRCULATIONAHA.116.026910.

25. Di Marco A, Anguera I, Schmitt M, et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. JACC Heart Fail. 2017; 5 (1): 28-38. DOI: 10.1016/j.jchf.2016.09.017.

26. Arbustini E, Disertori M, Narula J. Primary Prevention of Sudden Arrhythmic Death in Dilated Cardiomyopathy: Current Guidelines and Risk Stratification. JACC Heart Fail. 2017; 5 (1): 39-43. DOI: 10.1016/j.jchf.2016.11.009.

27. Blagova OV, Nedostup AV, Kogan EA, et al. DCMP as a clinical syndrome: results of nosological diagnostics with myocardial biopsy and differentiated treatment in viruspositive and virus-negative patients. Russian Journal of Cardiology. 2016; 1 (129): 7-19. (In Russ.) Благова О. В., Недоступ А. В., Коган Е. А., и др. ДКМП как клинический синд ром: результаты нозологической диагностики с применением биопсии миокарда и дифференцированного лечения у вирус-позитивных и вирус-негативных больных. Российский кардиологический журнал. 2016; 1 (129): 7-19. DOI: 10.15829/15604071-2016-1-7-19.